These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18982009)

  • 1. Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review.
    Neovius M; Narbro K
    Int J Obes (Lond); 2008 Dec; 32(12):1752-63. PubMed ID: 18982009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.
    Ara R; Blake L; Gray L; Hernández M; Crowther M; Dunkley A; Warren F; Jackson R; Rees A; Stevenson M; Abrams K; Cooper N; Davies M; Khunti K; Sutton A
    Health Technol Assess; 2012; 16(5):iii-xiv, 1-195. PubMed ID: 22340890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rimonabant for the treatment of overweight and obese people.
    Burch J; McKenna C; Palmer S; Norman G; Glanville J; Sculpher M; Woolacott N
    Health Technol Assess; 2009 Oct; 13 Suppl 3():13-22. PubMed ID: 19846024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden : a treatment responder approach.
    Hertzman P
    Pharmacoeconomics; 2005; 23(10):1007-20. PubMed ID: 16235974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
    Lacey LA; Wolf A; O'shea D; Erny S; Ruof J
    Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of sibutramine in the treatment of obesity.
    Warren E; Brennan A; Akehurst R
    Med Decis Making; 2004; 24(1):9-19. PubMed ID: 15005950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
    Avenell A; Broom J; Brown TJ; Poobalan A; Aucott L; Stearns SC; Smith WC; Jung RT; Campbell MK; Grant AM
    Health Technol Assess; 2004 May; 8(21):iii-iv, 1-182. PubMed ID: 15147610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacotherapy in the treatment of obesity].
    Hamann A
    MMW Fortschr Med; 2006 Mar; 148(9):36-8. PubMed ID: 16566392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany.
    Brennan A; Ara R; Sterz R; Matiba B; Bergemann R
    Eur J Health Econ; 2006 Dec; 7(4):276-84. PubMed ID: 17063345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of rimonabant in the treatment of obesity.
    Hampp C; Hartzema AG; Kauf TL
    Value Health; 2008; 11(3):389-99. PubMed ID: 18179661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases.
    van Baal PH; van den Berg M; Hoogenveen RT; Vijgen SM; Engelfriet PM
    Value Health; 2008 Dec; 11(7):1033-40. PubMed ID: 18494748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort.
    Douglas IJ; Bhaskaran K; Batterham RL; Smeeth L
    Br J Clin Pharmacol; 2015 Jun; 79(6):1020-7. PubMed ID: 25641659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity drug therapy.
    Baretić M
    Minerva Endocrinol; 2013 Sep; 38(3):245-54. PubMed ID: 24126545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity and cardiovascular physiology: impact of some pharmacological agents.
    Chaput JP; Bérubé-Parent S; Tremblay A
    Curr Vasc Pharmacol; 2005 Apr; 3(2):185-93. PubMed ID: 15853638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacotherapy for obesity: current drugs and those in advanced development.
    Halford JC
    Curr Drug Targets; 2004 Oct; 5(7):637-46. PubMed ID: 15473253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug treatment of obesity].
    Svendsen OL; Toubro S; Breum L; Bruun JM; Astrup AV
    Ugeskr Laeger; 2006 Jan; 168(2):163-7. PubMed ID: 16403342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
    Johansson K; Neovius K; DeSantis SM; Rössner S; Neovius M
    Obes Rev; 2009 Sep; 10(5):564-75. PubMed ID: 19460116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.
    Rubio MA; Gargallo M; Isabel Millán A; Moreno B
    Public Health Nutr; 2007 Oct; 10(10A):1200-5. PubMed ID: 17903331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.